5-Methoxy-UTP | 847649-65-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: 5-Methoxy-UTP
• 英文别名: ((2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methoxy-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate；[[(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methoxy-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
• CAS: 847649-65-4
• 化学式: C₁₀H₁₇N₂O₁₆P₃
• 分子量: 514.17
• InChiKey: ULUMTYRKOVZPNM-JXOAFFINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  268
• 氢给体数：
  7
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  5-甲氧基尿苷 在 1,8-双二甲氨基萘 、 三氯氧磷 作用下， 反应 2.17h， 生成 5-Methoxy-UTP
  参考文献：
  名称：

  [EN] ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF
  [FR] MOLÉCULES D'ACIDE NUCLÉIQUE ALTERNATIVES ET LEURS UTILISATIONS

  摘要：

  公开号：

  WO2015196128A3

文献信息

• [EN] URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DU DI- OU TRIPHOSPHATE D'URIDINE ET LEURS UTILISATIONS
  申请人：UNIV BAR ILAN

  公开号：WO2012073237A1

  公开（公告）日：2012-06-07

  The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and/or glaucoma.

  该发明提供了特定的脲苷二磷酸和三磷酸衍生物，以及其药用组合物。这些化合物可用于治疗受P2Y6受体调节的疾病、紊乱和病况，特别是降低眼内压，从而治疗眼压高和/或青光眼。
• RECOMBINANT NUCLEIC ACID CONSTRUCT AND USE THEREOF
  申请人：Pantherna Therapeutics GmbH

  公开号：EP3865579A1

  公开（公告）日：2021-08-18

  The present invention is related to a recombinant nucleic acid construct comprising in 5'-> 3' direction - a 5' UTR, - a coding region coding for an effector molecule, and - a 3' UTR, wherein the 5' UTR is selected from the group consisting of a 5' UTR of a gene coding for MCP-1 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for Ang-2 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for H3.3. or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for Galectin-9 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for GADD34 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for EDN1 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for HSP70m5 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for E-selectin or a derivative thereof having a nucleotide identity of at least 85 % a 5' UTR of a gene coding for ICAM-1 or a derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for IL-6 or a derivative thereof having a nucleotide identity of at least 85 % and a 5' UTR of a gene coding for vWF or a derivative thereof having a nucleotide identity of at least 85 %; wherein 3' UTR is selected from the group consisting of a 3' UTR of a gene coding for vWF or a derivative thereof having a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for MCP-1 or a derivative thereof having a nucleotide identity of at least 85 %,, a 3' UTR of a gene coding for RPL12s.c. or a derivative thereof having a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for H3.3. or a derivative thereof having a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for GADD34 or a derivative thereof having a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for EDN1 or a derivative thereof having a nucleotide identity of at least 85 %, and a 3' UTR of a gene coding for IL-6 or a derivative thereof having a nucleotide identity of at least 85 %, wherein the effector molecule is effective in restoring a cellular function of a cell or is effective in exercising a therapeutic effect in or on a cell, and wherein the recombinant nucleic acid construct is different from a wild type mRNA coding for the effector molecule.

  本发明涉及一种重组核酸构建体，该构建体在 5'-> 3'方向上包括 - 一个 5' UTR - 编码效应分子的编码区，以及 - 3' UTR、 其中 5'UTR选自由核苷酸同一性至少为 85%的 MCP-1或其衍生物编码基因的 5'UTR、RPL12s.c.或其衍生物编码基因的 5'UTR、RPL12s.c.或其衍生物编码基因的 5'UTR组成的组。或其衍生物的 5'UTR，其核苷酸同一性至少为 85%；Ang-2 编码基因的 5'UTR，或其衍生物的 5'UTR，其核苷酸同一性至少为 85%；HSP70 编码基因的 5'UTR，或其衍生物的 5'UTR，其核苷酸同一性至少为 85%；H3.3 编码基因的 5'UTR，或其衍生物的 5'UTR，其核苷酸同一性至少为 85%。或其衍生物的 5'UTR，其核苷酸同一性至少为 85%；Galectin-9 编码基因的 5'UTR，或其衍生物，其核苷酸同一性至少为 85%；GADD34 编码基因的 5'UTR，或其衍生物，其核苷酸同一性至少为 85%、核苷酸同一性至少为 85%的 EDN1 编码基因或其衍生物的 5'UTR， 核苷酸同一性至少为 85%的 HSP70m5 编码基因或其衍生物的 5'UTR、编码 E-选择素的基因或其衍生物的 5'UTR，其核苷酸同一性至少为 85%； 编码 ICAM-1 的基因或其衍生物的 5'UTR，其核苷酸同一性至少为 85%； 编码 IL-6 的基因或其衍生物的 5'UTR，其核苷酸同一性至少为 85%； 编码 vWF 的基因或其衍生物的 5'UTR，其核苷酸同一性至少为 85%； 其中 3'UTR选自由下列基因组成的组: vWF编码基因或其衍生物的3'UTR，其核苷酸同一性至少为85%；MCP-1编码基因或其衍生物的3'UTR，其核苷酸同一性至少为85%；RPL12s编码基因的3'UTR，其核苷酸同一性至少为85%；MCP-1编码基因或其衍生物的3'UTR，其核苷酸同一性至少为85%；RPL12s编码基因的3'UTR，其核苷酸同一性至少为85%。c. 或其衍生物，其核苷酸同一性至少为 85%； HSP70 编码基因的 3' UTR 或其衍生物，其核苷酸同一性至少为 85%； H3 编码基因的 3' UTR。或其衍生物的 3'UTR，其核苷酸同一性至少为 85%；编码 GADD34 的基因的 3'UTR，或其衍生物的 3'UTR，其核苷酸同一性至少为 85%；编码 EDN1 的基因的 3'UTR，或其衍生物的 3'UTR，其核苷酸同一性至少为 85%；编码 IL-6 的基因的 3'UTR，或其衍生物的 3'UTR，其核苷酸同一性至少为 85%、 其中所述效应分子可有效恢复细胞的细胞功能，或可有效发挥细胞内或细胞上的治疗作用，以及 其中重组核酸构建体不同于编码该效应分子的野生型 mRNA。
• Nucleic acid products and methods of administration thereof
  申请人：Factor Bioscience Inc.

  公开号：US10137206B2

  公开（公告）日：2018-11-27

  The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

  本发明部分涉及核酸，包括编码蛋白质的核酸，包含核酸的治疗剂和化妆品，向细胞、组织、器官和患者输送核酸的方法，使用核酸诱导细胞表达蛋白质的方法，用于转染、基因编辑和重编程细胞的方法、试剂盒和装置，以及使用这些方法、试剂盒和装置生产的细胞、生物体、治疗剂和化妆品。
• Metabolically stabilized double stranded mRNA
  申请人：University of Iowa Research Foundation

  公开号：US11007213B2

  公开（公告）日：2021-05-18

  Double stranded mRNA (ds mRNA), e.g., produced in vitro, where one strand encodes a protein of interest and the other strand is hydrogen bonded to at least a portion of the coding region for the protein, as well as methods of making and using the ds mRNA, are provided.

  提供了双链 mRNA（ds mRNA），例如在体外产生的双链 mRNA（ds mRNA），其中一条链编码感兴趣的蛋白质，另一条链与蛋白质编码区的至少一部分氢键结合，还提供了制造和使用 ds mRNA 的方法。
• Systems and methods for data storage in nucleic acids
  申请人：Bishop Bryan

  公开号：US11339423B2

  公开（公告）日：2022-05-24

  Provided are methods and systems for encoding data into nucleic acid molecules. Methods and systems disclosed can include the use of promiscuous template nucleic acid molecules which enables data encoding using environmental modifications to yield encoded nucleic acid molecules.

  本文提供了将数据编码到核酸分子中的方法和系统。所公开的方法和系统可包括使用杂乱的模板核酸分子，从而利用环境修饰进行数据编码，产生编码的核酸分子。